Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 153

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 153
---
 Warrant represents the right to purchase one Depositary Share at an exercise price of $0.0025 per share. TheJuly 2024 Pre-Funded Warrants are exercisable immediately and may be exercised at any time until theJuly 2024 Pre-Funded Warrants are exercised in full.

Additionally,
in the concurrent July 2024 Private Placement, we issued and sold to the Investors (i) Series J Warrants exercisable for 213,188 Depositary
Shares, and (ii) Series K Warrants to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at
an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The Series J Warrants
will expire five years from the initial exercise date and the Series K Warrants will expire one year from the initial exercise date. The
Investors (together with their respective affiliates) may not exercise the warrants if the Investor would beneficially own more than 4.99%
or 9.99% (such amount to be determined at the option of the Investor upon issuance) of the number of Ordinary Shares outstanding immediately
after giving effect to such exercise. The July Purchase Agreement contains customary representations, warranties and covenants of the
Company and each Investor, and customary indemnification provisions for a transaction of this type. Pursuant to the terms of the July
Purchase Agreement, we agreed to be subject to a lock-up period on subsequent equity sales, which has since expired. We also agreed to
not issue any securities that are subject to a price reset based on the trading prices of our Ordinary Shares or upon a specified or contingent
event in the future or enter into any agreement to issue securities at a future determined price for a period of 180 days following the
closing date of the Offerings, subject to certain exceptions. Additionally, we agreed to reduce the exercise price of our existing Series
E warrants, Series G warrants and Series H warrants held by each Investor to $25.00 per Depositary Share.

In
connection with the Offerings, we entered into a Placement Agent Agreement with Ladenburg, pursuant to which we engaged Ladenburg as the
exclusive placement agent for the Offerings. We agreed to pay Ladenburg a cash fee in an amount equal to 8.0% of the aggregate gross proceeds
of the Offerings and to issue to Ladenburg or its designees the July 2024 Placement Agent Warrants. We